Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Raniv D. Rojo, Joy Vanessa D. Perez, Jossana A. Damasco, Guoyu Yu, Song-Chang Lin, Francisco M. Heralde$suffix/text()$suffix/text(), Nora M. Novone, Elmer B. Santos, Sue-Hwa Lin & Marites P. Melancon. (2021) Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice. International Journal of Hyperthermia 38:1, pages 650-662.
Read now
Read now
Articles from other publishers (50)
M. V. Suryanarayana. (2023) Laser isotope separation of 223Ra. Scientific Reports 13:1.
Crossref
Crossref
Fabio Turco, Marcello Tucci, Tiziana Angusti, Antonella Parente, Rosario Francesco Di Stefano, Susanna Urban, Chiara Pisano, Alessandro Samuelly, Alessandro Audisio, Marco Audisio, Elena Parlagreco, Antonio Ungaro, Giorgio Vittorio Scagliotti, Massimo Di Maio & Consuelo Buttigliero. (2022) Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. Tumori Journal 109:2, pages 233-243.
Crossref
Crossref
Jeremie Calais, Stephen M. Eulau, Linda Gardner, Ralph J. Hauke, Ayse T. Kendi, Neal D. Shore & Song Zhao. (2023) Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treatment Reviews 115, pages 102524.
Crossref
Crossref
Diana V. Maslov, Quinne Sember, Jason Cham & Munveer Bhangoo. (2023) A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer. Frontiers in Oncology 13.
Crossref
Crossref
Sofia Khabirova, Gleb Aleshin, Evgeny Anokhin, Anna Shchukina, Anastasia Zubenko, Olga Fedorova, Aleksey Averin, Lev Trusov & Stepan Kalmykov. (2023) Novel candidate theranostic radiopharmaceutical based on strontium hexaferrite nanoparticles conjugated with azacrown ligand. Dalton Transactions 52:6, pages 1731-1741.
Crossref
Crossref
Gen Kawaguchi, Kohei Akazawa, Taro Ikeda, Yohei Ikeda, Noboru Hara & Tsutomu Nishiyama. (2023) Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer. SAGE Open Medicine 11, pages 205031212311684.
Crossref
Crossref
Zekun Li, Nadia Benabdallah, Diane S. Abou, Brian C. Baumann, Farrokh Dehdashti, David H. Ballard, Jonathan Liu, Uday Jammalamadaka, Richard L. Laforest, Richard L Wahl, Daniel L. J. Thorek & Abhinav K. Jha. (2023) A Projection-Domain Low-Count Quantitative SPECT Method for ɑ-Particle-Emitting Radiopharmaceutical Therapy. IEEE Transactions on Radiation and Plasma Medical Sciences 7:1, pages 62-74.
Crossref
Crossref
Sarah Clements, Daniel Tempesta & Matthew Robertson. (2022)
223
Ra-Dichloride Therapy
. Journal of Nuclear Medicine Technology 50:3, pages 222-223.
Crossref
Crossref
Akiko Yamaguchi, Kojiro Nagata, Keita Kobayashi, Kazuya Tanaka, Tohru Kobayashi, Hajime Tanida, Kojiro Shimojo, Tetsuhiro Sekiguchi, Yui Kaneta, Shohei Matsuda, Keiichi Yokoyama, Tsuyoshi Yaita, Takashi Yoshimura, Masahiko Okumura & Yoshio Takahashi. (2022) Extended X-ray absorption fine structure spectroscopy measurements and ab initio molecular dynamics simulations reveal the hydration structure of the radium(II) ion. iScience 25:8, pages 104763.
Crossref
Crossref
Fang-Yi Su, Giordano Biasi, Linh T. Tran, Vladimir Pan, Dylan Hill, Mitchell Lielkajis, Dean Cutajar, Marco Petasecca, Michael Lerch, Zeljko Pastuovic, Joel Poder, Joseph Bucci, Michael Jackson & Anatoly B. Rosenfeld. (2022) Characterization of MOSFET Dosimeters for Alpha Particle Therapy. IEEE Transactions on Nuclear Science 69:4, pages 925-931.
Crossref
Crossref
Aleksandra Sochacka-Ćwikła, Marcin Mączyński & Andrzej Regiec. (2022) FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 27:7, pages 2259.
Crossref
Crossref
Michael A. Harris & Christine J. Hawkins. (2022) Recent and Ongoing Research into Metastatic Osteosarcoma Treatments. International Journal of Molecular Sciences 23:7, pages 3817.
Crossref
Crossref
Melyssa L. Grieve & Brett M. Paterson. (2021) The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy. Australian Journal of Chemistry 75:2, pages 65-88.
Crossref
Crossref
Caibin Fan, Wei Lu, Kai Li, Chunchun Zhao, Fei Wang, Guanxiong Ding & Jianqing Wang. (2021) Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. Cancer Biomarkers 32:3, pages 363-377.
Crossref
Crossref
Natalia Herrero Álvarez, David Bauer, Javier Hernández‐Gil & Jason S. Lewis. (2021) Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 16:19, pages 2909-2941.
Crossref
Crossref
Kalevi Kairemo, Jason Roszik, Pete Anderson, Gregory Ravizzini, Arvind Rao, Homer A. Macapinlac & Vivek Subbiah. (2021) 18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Current Problems in Cancer 45:5, pages 100797.
Crossref
Crossref
Esmail M. Al‐Ezzi, Husam A. Alqaisi, Marco A. J. Iafolla, Lisa Wang, Srikala S. Sridhar, Adrian G. Sacher, Nazanin Fallah‐Rad, Di M. Jiang, Geoffrey A. Watson, Charles N. Catton, Padraig R. Warde, Rob J. Hamilton, Neil E. Fleshner, Alexandre R. Zlotta & Aaron R. Hansen. (2021) Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223. Cancer Medicine 10:17, pages 5775-5782.
Crossref
Crossref
Mohamed El Fakiri, Nicolas M. Geis, Nawal Ayada, Matthias Eder & Ann-Christin Eder. (2021) PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers 13:16, pages 3967.
Crossref
Crossref
Falco Reissig, Klaus Kopka & Constantin Mamat. (2021) The impact of barium isotopes in radiopharmacy and nuclear medicine – From past to presence. Nuclear Medicine and Biology 98-99, pages 59-68.
Crossref
Crossref
Falco Reissig, Klaus Kopka & Constantin Mamat. (2021) Die Bedeutung des Elementes Barium in der Nuklearmedizin. Der Nuklearmediziner 44:02, pages 127-134.
Crossref
Crossref
Julie Constanzo, Julien Faget, Chiara Ursino, Christophe Badie & Jean-Pierre Pouget. (2021) Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway. Frontiers in Immunology 12.
Crossref
Crossref
Jasmin Katrin Badawi. (2021) Bee Venom Components as Therapeutic Tools against Prostate Cancer. Toxins 13:5, pages 337.
Crossref
Crossref
Tyrillshall S. T. Damiana & Simone U. Dalm. (2021) Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. Pharmaceutics 13:5, pages 674.
Crossref
Crossref
Daria Klusa, Fabian Lohaus, Giulia Furesi, Martina Rauner, Martina Benešová, Mechthild Krause, Ina Kurth & Claudia Peitzsch. (2021) Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. Frontiers in Oncology 10.
Crossref
Crossref
Meera Venkatesh & Keon Wook Kang. 2021. Encyclopedia of Nuclear Energy. Encyclopedia of Nuclear Energy
236
260
.
Siddhartha Nagireddy, Rehana Qureshi, Jordan Best, Fabio Stefano Frech, Khushi Shah, Yash Soni, Manish Kuchakulla, Manish Narasimman & Himanshu Arora. 2021. Tumor Microenvironment. Tumor Microenvironment
295
323
.
Stefano Casarin & Eleonora Dondossola. (2020) An agent-based model of prostate Cancer bone metastasis progression and response to Radium223. BMC Cancer 20:1.
Crossref
Crossref
Hamza Hasan, Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan, Ana P. Kiess, Shirl Dipasquale, James Huang, Terry Caldwell, Jessica Leitzel, Danielle Wendler, Hao Wang, Elizabeth Thompson, Jonathan Powell, Sara Dudley, Curtiland Deville, Stephen C. Greco, Daniel Y. Song, Theodore L. DeWeese, Michael A. Gorin, Steven P. Rowe, Sam Denmeade, Mark Markowski, Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Channing J. Paller & Phuoc T. Tran. (2020) A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer 20:1.
Crossref
Crossref
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé & Michal Grzmil. (2020) Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy. Pharmaceutics 12:11, pages 1088.
Crossref
Crossref
Mona Kafka, Iris E. Eder, Helmut Klocker & Isabel Heidegger. (2020) Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations 38:11, pages 801-815.
Crossref
Crossref
Alessandra Raimondi, Pierangela Sepe, Melanie Claps, Marco Maccauro, Gianluca Aliberti, Filippo Pagani, Giulia Apollonio, Giovanni Randon, Giorgia Peverelli, Ettore Seregni, Elena Verzoni & Giuseppe Procopio. (2020) Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Tumori Journal 106:5, pages 406-412.
Crossref
Crossref
Orazio Caffo, Viviana Frantellizzi, Marcello Tucci, Luca Galli, Fabio Monari, Sergio Baldari, Cristina Masini, Roberto Bortolus, Gaetano Facchini, Pierpaolo Alongi, Stefania Agostini, Clizia Zichi, Elisa Biasco, Stefano Fanti, Salvatore Pignata, Angelina Filice, Eugenio Borsatti, Sabrina Rossetti, Massimiliano Spada, Enrico Cortesi & Giuseppe De Vincentis. (2020) Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. European Journal of Nuclear Medicine and Molecular Imaging 47:11, pages 2633-2638.
Crossref
Crossref
Lakshay Jain, S. V. Thakare & Kondayya Gundra. (2020) Theoretical investigation for optimizing the production of 223Ra in research reactors for treatment of bone metastases. Journal of Radioanalytical and Nuclear Chemistry 325:3, pages 905-911.
Crossref
Crossref
Mine Silindir-GunayMerve KarpuzA. Yekta Ozer. (2020) Targeted Alpha Therapy and Nanocarrier Approach. Cancer Biotherapy and Radiopharmaceuticals 35:6, pages 446-458.
Crossref
Crossref
Albert Jang, Shuang R. Chen, John Xie, Mehmet A. Bilen & Pedro C. Barata. (2020) Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review. Kidney Cancer 4:2, pages 93-102.
Crossref
Crossref
Minh-Phuong Huynh-Le, Randall C. Shults, Michael J. Connor & Jona A. Hattangadi-Gluth. (2020) Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization. Clinical Genitourinary Cancer 18:3, pages 192-200.e2.
Crossref
Crossref
Elisa Lodi Rizzini, Valeria Dionisi, Pietro Ghedini, Alessio Giuseppe Morganti, Stefano Fanti & Fabio Monari. (2020) Clinical aspects of mCRPC management in patients treated with radium-223. Scientific Reports 10:1.
Crossref
Crossref
Nadia Benabdallah, Michela Bernardini, Marta Bianciardi, Claire de Labriolle-Vaylet, Didier Franck & Aurélie Desbrée. (2019) 223Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification. EJNMMI Research 9:1.
Crossref
Crossref
Michael J. Morris, Eva Corey, Theresa A. Guise, James L. Gulley, William Kevin Kelly, David I. Quinn, Arne Scholz & George Sgouros. (2019) Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology 16:12, pages 745-756.
Crossref
Crossref
Vincenzo Serretta, Maria Rosaria Valerio, Renato Costa, Vincenzo Tripoli, Alessandra Murabito, Alessandro Princiotta, Cristina Scalici Gesolfo, Nicolò Borsellino, Francesco Verderame, Vittorio Gebbia, Maria Licari & Chiara Sanfilippo. (2019) Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?. Urologic Oncology: Seminars and Original Investigations 37:12, pages 964-969.
Crossref
Crossref
Yinchu Cheng, Lin Zhuo, Yuting Pan, Shengfeng Wang, Jihong Zong, Wentao Sun, Shuangqing Gao, Jian Lu & Siyan Zhan. (2019) Treatment patterns of prostate cancer with bone metastasis in Beijing: A real‐world study using data from an administrative claims database. Pharmacoepidemiology and Drug Safety 28:11, pages 1501-1509.
Crossref
Crossref
Bartosz Malinowski, Michał Wiciński, Nikola Musiała, Ilona Osowska & Mateusz Szostak. (2019) Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer—A Comprehensive Review. Diagnostics 9:4, pages 161.
Crossref
Crossref
Christopher J. Tichacek, Mikalai M. Budzevich, Thaddeus J. Wadas, David L. Morse & Eduardo G. Moros. (2019) A Monte Carlo Method for Determining the Response Relationship between Two Commonly Used Detectors to Indirectly Measure Alpha Particle Radiation Activity. Molecules 24:18, pages 3397.
Crossref
Crossref
Vivek Subbiah, Pete M. Anderson, Kalevi Kairemo, Kenneth Hess, Winston W. Huh, Vinod Ravi, Najat C. Daw, Neeta Somaiah, Joseph A. Ludwig, Robert S. Benjamin, Sant Chawla, David S. Hong, Funda Meric-Bernstam, Gregory Ravizzini, Eugenie Kleinerman, Homer Macapinlac & Eric Rohren. (2019) Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research 25:13, pages 3802-3810.
Crossref
Crossref
Valentin Roque, Maryam Jessop, Luisa Pereira, Paul Gape, Sabina Dizdarevic, Eva Sousa & Elizabete Carolino. (2019) Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response. Nuclear Medicine Communications 40:6, pages 588-596.
Crossref
Crossref
Simon Linder, Henk G van der Poel, Andries M Bergman, Wilbert Zwart & Stefan Prekovic. (2019) Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocrine-Related Cancer 26:1, pages R31-R52.
Crossref
Crossref
Anthony DiNatale & Alessandro Fatatis. 2019. Prostate Cancer. Prostate Cancer
171
184
.
Beata Kiselova Bilekova, Beata Gavurova & Vladimír Rogalewicz. (2018) Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer. Health Economics Review 8:1.
Crossref
Crossref
Courtney Jarvis, Thomas Nelius, Dalia Martinez-Marin, Souad R. Sennoune & Stéphanie Filleur. (2018) Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity. The Prostate 78:12, pages 905-914.
Crossref
Crossref
Vikki Cantrill. (2018) The realities of radium. Nature Chemistry 10:8, pages 898-898.
Crossref
Crossref